ベムラフェニブのグローバル市場インサイト・予測（～2028年）

• 英文タイトル：Global Vemurafenib Market Insights, Forecast to 2028

• レポートコード：QY2207E02840 • 出版社/出版日：QYResearch / 2022年7月 • レポート形態：英文、PDF、91ページ • 納品方法：Eメール（納期：3日） • 産業分類：化学＆材料

• 販売価格（消費税別）

Single User	￥725,200 (USD4,900)	▷ お問い合わせ
Multi User	￥1,087,800 (USD7,350)	▷ お問い合わせ
Enterprise License	￥1,450,400 (USD9,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

新型コロナウイルス感染症のパンデミックにより、世界のベムラフェニブの市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年にベムラフェニブの世界市場のxxx％を占める「純度≥99％」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「医薬品」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。 中国のベムラフェニブの市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパのベムラフェニブ市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパのベムラフェニブ市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。 ベムラフェニブのグローバル主要メーカーには、Fermion、Roche、Haohong Biotechnology、LGM Pharma、KeChow Pharma、Hetero、ANQING CHICO、Shanghai Shenyue Biotechnology、Kaiyu Pharmatechなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 ベムラフェニブ市場は、種類と用途によって区分されます。世界のベムラフェニブ市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。 【種類別セグメント】 純度≥99％、純度≥99.5％ 【用途別セグメント】 医薬品、研究用試薬、その他 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - ベムラフェニブ製品概要 - 種類別市場（純度≥99％、純度≥99.5％） - 用途別市場（医薬品、研究用試薬、その他） - 調査の目的 ・エグゼクティブサマリー - 世界のベムラフェニブ販売量予測2017-2028 - 世界のベムラフェニブ売上予測2017-2028 - ベムラフェニブの地域別販売量 - ベムラフェニブの地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別ベムラフェニブ販売量 - 主要メーカー別ベムラフェニブ売上 - 主要メーカー別ベムラフェニブ価格 - 競争状況の分析 - 企業M&A動向 ・種類別市場規模（純度≥99％、純度≥99.5％） - ベムラフェニブの種類別販売量 - ベムラフェニブの種類別売上 - ベムラフェニブの種類別価格 ・用途別市場規模（医薬品、研究用試薬、その他） - ベムラフェニブの用途別販売量 - ベムラフェニブの用途別売上 - ベムラフェニブの用途別価格 ・北米市場 - 北米のベムラフェニブ市場規模（種類別、用途別） - 主要国別のベムラフェニブ市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパのベムラフェニブ市場規模（種類別、用途別） - 主要国別のベムラフェニブ市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋のベムラフェニブ市場規模（種類別、用途別） - 主要国別のベムラフェニブ市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米のベムラフェニブ市場規模（種類別、用途別） - 主要国別のベムラフェニブ市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカのベムラフェニブ市場規模（種類別、用途別） - 主要国別のベムラフェニブ市場規模（トルコ、サウジアラビア） ・企業情報 Fermion、Roche、Haohong Biotechnology、LGM Pharma、KeChow Pharma、Hetero、ANQING CHICO、Shanghai Shenyue Biotechnology、Kaiyu Pharmatech ・産業チェーン及び販売チャネル分析 - ベムラフェニブの産業チェーン分析 - ベムラフェニブの原材料 - ベムラフェニブの生産プロセス - ベムラフェニブの販売及びマーケティング - ベムラフェニブの主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - ベムラフェニブの産業動向 - ベムラフェニブのマーケットドライバー - ベムラフェニブの課題 - ベムラフェニブの阻害要因 ・主な調査結果

Market Analysis and Insights: Global Vemurafenib Market
Due to the COVID-19 pandemic, the global Vemurafenib market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, Purity ≥99% accounting for % of the Vemurafenib global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Pharmaceutical segment is altered to an % CAGR throughout this forecast period.
China Vemurafenib market size is valued at US$ million in 2021, while the US and Europe Vemurafenib are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Vemurafenib landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
The global key manufacturers of Vemurafenib include Fermion, Roche, Haohong Biotechnology, LGM Pharma, KeChow Pharma, Hetero, ANQING CHICO, Shanghai Shenyue Biotechnology and Kaiyu Pharmatech. etc. In 2021, the global top five players have a share approximately % in terms of revenue.
In terms of production side, this report researches the Vemurafenib capacity, production, growth rate, market share by manufacturers and by region (region level and country level), from 2017 to 2022, and forecast to 2028.
In terms of sales side, this report focuses on the sales of Vemurafenib by region (region level and country level), by company, by Type and by Application. from 2017 to 2022 and forecast to 2028.
Global Vemurafenib Scope and Segment
Vemurafenib market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Vemurafenib market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on production capacity, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Purity ≥99%
Purity ≥99.5%
Segment by Application
Pharmaceutical
Research Reagents
Other
By Company
Fermion
Roche
Haohong Biotechnology
LGM Pharma
KeChow Pharma
Hetero
ANQING CHICO
Shanghai Shenyue Biotechnology
Kaiyu Pharmatech
Production by Region
North America
Europe
China
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

レポート目次

---

1 Study Coverage
1.1 Vemurafenib Product Introduction
1.2 Market by Type
1.2.1 Global Vemurafenib Market Size by Type, 2017 VS 2021 VS 2028
1.2.2 Purity ≥99%
1.2.3 Purity ≥99.5%
1.3 Market by Application
1.3.1 Global Vemurafenib Market Size by Application, 2017 VS 2021 VS 2028
1.3.2 Pharmaceutical
1.3.3 Research Reagents
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
2 Global Vemurafenib Production
2.1 Global Vemurafenib Production Capacity (2017-2028)
2.2 Global Vemurafenib Production by Region: 2017 VS 2021 VS 2028
2.3 Global Vemurafenib Production by Region
2.3.1 Global Vemurafenib Historic Production by Region (2017-2022)
2.3.2 Global Vemurafenib Forecasted Production by Region (2023-2028)
2.4 North America
2.5 Europe
2.6 China
3 Global Vemurafenib Sales in Volume & Value Estimates and Forecasts
3.1 Global Vemurafenib Sales Estimates and Forecasts 2017-2028
3.2 Global Vemurafenib Revenue Estimates and Forecasts 2017-2028
3.3 Global Vemurafenib Revenue by Region: 2017 VS 2021 VS 2028
3.4 Global Vemurafenib Sales by Region
3.4.1 Global Vemurafenib Sales by Region (2017-2022)
3.4.2 Global Sales Vemurafenib by Region (2023-2028)
3.5 Global Vemurafenib Revenue by Region
3.5.1 Global Vemurafenib Revenue by Region (2017-2022)
3.5.2 Global Vemurafenib Revenue by Region (2023-2028)
3.6 North America
3.7 Europe
3.8 Asia-Pacific
3.9 Latin America
3.10 Middle East & Africa
4 Competition by Manufactures
4.1 Global Vemurafenib Production Capacity by Manufacturers
4.2 Global Vemurafenib Sales by Manufacturers
4.2.1 Global Vemurafenib Sales by Manufacturers (2017-2022)
4.2.2 Global Vemurafenib Sales Market Share by Manufacturers (2017-2022)
4.2.3 Global Top 10 and Top 5 Largest Manufacturers of Vemurafenib in 2021
4.3 Global Vemurafenib Revenue by Manufacturers
4.3.1 Global Vemurafenib Revenue by Manufacturers (2017-2022)
4.3.2 Global Vemurafenib Revenue Market Share by Manufacturers (2017-2022)
4.3.3 Global Top 10 and Top 5 Companies by Vemurafenib Revenue in 2021
4.4 Global Vemurafenib Sales Price by Manufacturers
4.5 Analysis of Competitive Landscape
4.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
4.5.2 Global Vemurafenib Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.5.3 Global Vemurafenib Manufacturers Geographical Distribution
4.6 Mergers & Acquisitions, Expansion Plans
5 Market Size by Type
5.1 Global Vemurafenib Sales by Type
5.1.1 Global Vemurafenib Historical Sales by Type (2017-2022)
5.1.2 Global Vemurafenib Forecasted Sales by Type (2023-2028)
5.1.3 Global Vemurafenib Sales Market Share by Type (2017-2028)
5.2 Global Vemurafenib Revenue by Type
5.2.1 Global Vemurafenib Historical Revenue by Type (2017-2022)
5.2.2 Global Vemurafenib Forecasted Revenue by Type (2023-2028)
5.2.3 Global Vemurafenib Revenue Market Share by Type (2017-2028)
5.3 Global Vemurafenib Price by Type
5.3.1 Global Vemurafenib Price by Type (2017-2022)
5.3.2 Global Vemurafenib Price Forecast by Type (2023-2028)
6 Market Size by Application
6.1 Global Vemurafenib Sales by Application
6.1.1 Global Vemurafenib Historical Sales by Application (2017-2022)
6.1.2 Global Vemurafenib Forecasted Sales by Application (2023-2028)
6.1.3 Global Vemurafenib Sales Market Share by Application (2017-2028)
6.2 Global Vemurafenib Revenue by Application
6.2.1 Global Vemurafenib Historical Revenue by Application (2017-2022)
6.2.2 Global Vemurafenib Forecasted Revenue by Application (2023-2028)
6.2.3 Global Vemurafenib Revenue Market Share by Application (2017-2028)
6.3 Global Vemurafenib Price by Application
6.3.1 Global Vemurafenib Price by Application (2017-2022)
6.3.2 Global Vemurafenib Price Forecast by Application (2023-2028)
7 North America
7.1 North America Vemurafenib Market Size by Type
7.1.1 North America Vemurafenib Sales by Type (2017-2028)
7.1.2 North America Vemurafenib Revenue by Type (2017-2028)
7.2 North America Vemurafenib Market Size by Application
7.2.1 North America Vemurafenib Sales by Application (2017-2028)
7.2.2 North America Vemurafenib Revenue by Application (2017-2028)
7.3 North America Vemurafenib Sales by Country
7.3.1 North America Vemurafenib Sales by Country (2017-2028)
7.3.2 North America Vemurafenib Revenue by Country (2017-2028)
7.3.3 United States
7.3.4 Canada
8 Europe
8.1 Europe Vemurafenib Market Size by Type
8.1.1 Europe Vemurafenib Sales by Type (2017-2028)
8.1.2 Europe Vemurafenib Revenue by Type (2017-2028)
8.2 Europe Vemurafenib Market Size by Application
8.2.1 Europe Vemurafenib Sales by Application (2017-2028)
8.2.2 Europe Vemurafenib Revenue by Application (2017-2028)
8.3 Europe Vemurafenib Sales by Country
8.3.1 Europe Vemurafenib Sales by Country (2017-2028)
8.3.2 Europe Vemurafenib Revenue by Country (2017-2028)
8.3.3 Germany
8.3.4 France
8.3.5 U.K.
8.3.6 Italy
8.3.7 Russia
9 Asia Pacific
9.1 Asia Pacific Vemurafenib Market Size by Type
9.1.1 Asia Pacific Vemurafenib Sales by Type (2017-2028)
9.1.2 Asia Pacific Vemurafenib Revenue by Type (2017-2028)
9.2 Asia Pacific Vemurafenib Market Size by Application
9.2.1 Asia Pacific Vemurafenib Sales by Application (2017-2028)
9.2.2 Asia Pacific Vemurafenib Revenue by Application (2017-2028)
9.3 Asia Pacific Vemurafenib Sales by Region
9.3.1 Asia Pacific Vemurafenib Sales by Region (2017-2028)
9.3.2 Asia Pacific Vemurafenib Revenue by Region (2017-2028)
9.3.3 China
9.3.4 Japan
9.3.5 South Korea
9.3.6 India
9.3.7 Australia
9.3.8 China Taiwan
9.3.9 Indonesia
9.3.10 Thailand
9.3.11 Malaysia
10 Latin America
10.1 Latin America Vemurafenib Market Size by Type
10.1.1 Latin America Vemurafenib Sales by Type (2017-2028)
10.1.2 Latin America Vemurafenib Revenue by Type (2017-2028)
10.2 Latin America Vemurafenib Market Size by Application
10.2.1 Latin America Vemurafenib Sales by Application (2017-2028)
10.2.2 Latin America Vemurafenib Revenue by Application (2017-2028)
10.3 Latin America Vemurafenib Sales by Country
10.3.1 Latin America Vemurafenib Sales by Country (2017-2028)
10.3.2 Latin America Vemurafenib Revenue by Country (2017-2028)
10.3.3 Mexico
10.3.4 Brazil
10.3.5 Argentina
11 Middle East and Africa
11.1 Middle East and Africa Vemurafenib Market Size by Type
11.1.1 Middle East and Africa Vemurafenib Sales by Type (2017-2028)
11.1.2 Middle East and Africa Vemurafenib Revenue by Type (2017-2028)
11.2 Middle East and Africa Vemurafenib Market Size by Application
11.2.1 Middle East and Africa Vemurafenib Sales by Application (2017-2028)
11.2.2 Middle East and Africa Vemurafenib Revenue by Application (2017-2028)
11.3 Middle East and Africa Vemurafenib Sales by Country
11.3.1 Middle East and Africa Vemurafenib Sales by Country (2017-2028)
11.3.2 Middle East and Africa Vemurafenib Revenue by Country (2017-2028)
11.3.3 Turkey
11.3.4 Saudi Arabia
11.3.5 UAE
12 Corporate Profiles
12.1 Fermion
12.1.1 Fermion Corporation Information
12.1.2 Fermion Overview
12.1.3 Fermion Vemurafenib Sales, Price, Revenue and Gross Margin (2017-2022)
12.1.4 Fermion Vemurafenib Product Model Numbers, Pictures, Descriptions and Specifications
12.1.5 Fermion Recent Developments
12.2 Roche
12.2.1 Roche Corporation Information
12.2.2 Roche Overview
12.2.3 Roche Vemurafenib Sales, Price, Revenue and Gross Margin (2017-2022)
12.2.4 Roche Vemurafenib Product Model Numbers, Pictures, Descriptions and Specifications
12.2.5 Roche Recent Developments
12.3 Haohong Biotechnology
12.3.1 Haohong Biotechnology Corporation Information
12.3.2 Haohong Biotechnology Overview
12.3.3 Haohong Biotechnology Vemurafenib Sales, Price, Revenue and Gross Margin (2017-2022)
12.3.4 Haohong Biotechnology Vemurafenib Product Model Numbers, Pictures, Descriptions and Specifications
12.3.5 Haohong Biotechnology Recent Developments
12.4 LGM Pharma
12.4.1 LGM Pharma Corporation Information
12.4.2 LGM Pharma Overview
12.4.3 LGM Pharma Vemurafenib Sales, Price, Revenue and Gross Margin (2017-2022)
12.4.4 LGM Pharma Vemurafenib Product Model Numbers, Pictures, Descriptions and Specifications
12.4.5 LGM Pharma Recent Developments
12.5 KeChow Pharma
12.5.1 KeChow Pharma Corporation Information
12.5.2 KeChow Pharma Overview
12.5.3 KeChow Pharma Vemurafenib Sales, Price, Revenue and Gross Margin (2017-2022)
12.5.4 KeChow Pharma Vemurafenib Product Model Numbers, Pictures, Descriptions and Specifications
12.5.5 KeChow Pharma Recent Developments
12.6 Hetero
12.6.1 Hetero Corporation Information
12.6.2 Hetero Overview
12.6.3 Hetero Vemurafenib Sales, Price, Revenue and Gross Margin (2017-2022)
12.6.4 Hetero Vemurafenib Product Model Numbers, Pictures, Descriptions and Specifications
12.6.5 Hetero Recent Developments
12.7 ANQING CHICO
12.7.1 ANQING CHICO Corporation Information
12.7.2 ANQING CHICO Overview
12.7.3 ANQING CHICO Vemurafenib Sales, Price, Revenue and Gross Margin (2017-2022)
12.7.4 ANQING CHICO Vemurafenib Product Model Numbers, Pictures, Descriptions and Specifications
12.7.5 ANQING CHICO Recent Developments
12.8 Shanghai Shenyue Biotechnology
12.8.1 Shanghai Shenyue Biotechnology Corporation Information
12.8.2 Shanghai Shenyue Biotechnology Overview
12.8.3 Shanghai Shenyue Biotechnology Vemurafenib Sales, Price, Revenue and Gross Margin (2017-2022)
12.8.4 Shanghai Shenyue Biotechnology Vemurafenib Product Model Numbers, Pictures, Descriptions and Specifications
12.8.5 Shanghai Shenyue Biotechnology Recent Developments
12.9 Kaiyu Pharmatech
12.9.1 Kaiyu Pharmatech Corporation Information
12.9.2 Kaiyu Pharmatech Overview
12.9.3 Kaiyu Pharmatech Vemurafenib Sales, Price, Revenue and Gross Margin (2017-2022)
12.9.4 Kaiyu Pharmatech Vemurafenib Product Model Numbers, Pictures, Descriptions and Specifications
12.9.5 Kaiyu Pharmatech Recent Developments
13 Industry Chain and Sales Channels Analysis
13.1 Vemurafenib Industry Chain Analysis
13.2 Vemurafenib Key Raw Materials
13.2.1 Key Raw Materials
13.2.2 Raw Materials Key Suppliers
13.3 Vemurafenib Production Mode & Process
13.4 Vemurafenib Sales and Marketing
13.4.1 Vemurafenib Sales Channels
13.4.2 Vemurafenib Distributors
13.5 Vemurafenib Customers
14 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
14.1 Vemurafenib Industry Trends
14.2 Vemurafenib Market Drivers
14.3 Vemurafenib Market Challenges
14.4 Vemurafenib Market Restraints
15 Key Finding in The Global Vemurafenib Study
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer

List of Tables
Table 1. Global Vemurafenib Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Purity ≥99%
Table 3. Major Manufacturers of Purity ≥99.5%
Table 4. Global Vemurafenib Market Size Growth Rate by Application, 2017 VS 2021 2028 (US$ Million)
Table 5. Global Vemurafenib Production by Region: 2017 VS 2021 VS 2028 (Tons)
Table 6. Global Vemurafenib Production by Region (2017-2022) & (Tons)
Table 7. Global Vemurafenib Production Market Share by Region (2017-2022)
Table 8. Global Vemurafenib Production by Region (2023-2028) & (Tons)
Table 9. Global Vemurafenib Production Market Share by Region (2023-2028)
Table 10. Global Vemurafenib Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 11. Global Vemurafenib Sales by Region (2017-2022) & (Tons)
Table 12. Global Vemurafenib Sales Market Share by Region (2017-2022)
Table 13. Global Vemurafenib Sales by Region (2023-2028) & (Tons)
Table 14. Global Vemurafenib Sales Market Share by Region (2023-2028)
Table 15. Global Vemurafenib Revenue by Region (2017-2022) & (US$ Million)
Table 16. Global Vemurafenib Revenue Market Share by Region (2017-2022)
Table 17. Global Vemurafenib Revenue by Region (2023-2028) & (US$ Million)
Table 18. Global Vemurafenib Revenue Market Share by Region (2023-2028)
Table 19. Global Vemurafenib Production Capacity by Manufacturers (2017-2022) & (Tons)
Table 20. Global Vemurafenib Capacity Market Share by Manufacturers (2017-2022)
Table 21. Global Vemurafenib Sales by Manufacturers (2017-2022) & (Tons)
Table 22. Global Vemurafenib Sales Market Share by Manufacturers (2017-2022)
Table 23. Global Vemurafenib Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 24. Global Vemurafenib Revenue Share by Manufacturers (2017-2022)
Table 25. Vemurafenib Price by Manufacturers 2017-2022 (US$/Ton)
Table 26. Global Vemurafenib Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 27. Global Vemurafenib by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Vemurafenib as of 2021)
Table 28. Vemurafenib Manufacturing Base Distribution and Headquarters
Table 29. Manufacturers Vemurafenib Product Offered
Table 30. Date of Manufacturers Enter into Vemurafenib Market
Table 31. Mergers & Acquisitions, Expansion Plans
Table 32. Global Vemurafenib Sales by Type (2017-2022) & (Tons)
Table 33. Global Vemurafenib Sales by Type (2023-2028) & (Tons)
Table 34. Global Vemurafenib Sales Share by Type (2017-2022)
Table 35. Global Vemurafenib Sales Share by Type (2023-2028)
Table 36. Global Vemurafenib Revenue by Type (2017-2022) & (US$ Million)
Table 37. Global Vemurafenib Revenue by Type (2023-2028) & (US$ Million)
Table 38. Global Vemurafenib Revenue Share by Type (2017-2022)
Table 39. Global Vemurafenib Revenue Share by Type (2023-2028)
Table 40. Vemurafenib Price by Type (2017-2022) & (US$/Ton)
Table 41. Global Vemurafenib Price Forecast by Type (2023-2028) & (US$/Ton)
Table 42. Global Vemurafenib Sales by Application (2017-2022) & (Tons)
Table 43. Global Vemurafenib Sales by Application (2023-2028) & (Tons)
Table 44. Global Vemurafenib Sales Share by Application (2017-2022)
Table 45. Global Vemurafenib Sales Share by Application (2023-2028)
Table 46. Global Vemurafenib Revenue by Application (2017-2022) & (US$ Million)
Table 47. Global Vemurafenib Revenue by Application (2023-2028) & (US$ Million)
Table 48. Global Vemurafenib Revenue Share by Application (2017-2022)
Table 49. Global Vemurafenib Revenue Share by Application (2023-2028)
Table 50. Vemurafenib Price by Application (2017-2022) & (US$/Ton)
Table 51. Global Vemurafenib Price Forecast by Application (2023-2028) & (US$/Ton)
Table 52. North America Vemurafenib Sales by Type (2017-2022) & (Tons)
Table 53. North America Vemurafenib Sales by Type (2023-2028) & (Tons)
Table 54. North America Vemurafenib Revenue by Type (2017-2022) & (US$ Million)
Table 55. North America Vemurafenib Revenue by Type (2023-2028) & (US$ Million)
Table 56. North America Vemurafenib Sales by Application (2017-2022) & (Tons)
Table 57. North America Vemurafenib Sales by Application (2023-2028) & (Tons)
Table 58. North America Vemurafenib Revenue by Application (2017-2022) & (US$ Million)
Table 59. North America Vemurafenib Revenue by Application (2023-2028) & (US$ Million)
Table 60. North America Vemurafenib Sales by Country (2017-2022) & (Tons)
Table 61. North America Vemurafenib Sales by Country (2023-2028) & (Tons)
Table 62. North America Vemurafenib Revenue by Country (2017-2022) & (US$ Million)
Table 63. North America Vemurafenib Revenue by Country (2023-2028) & (US$ Million)
Table 64. Europe Vemurafenib Sales by Type (2017-2022) & (Tons)
Table 65. Europe Vemurafenib Sales by Type (2023-2028) & (Tons)
Table 66. Europe Vemurafenib Revenue by Type (2017-2022) & (US$ Million)
Table 67. Europe Vemurafenib Revenue by Type (2023-2028) & (US$ Million)
Table 68. Europe Vemurafenib Sales by Application (2017-2022) & (Tons)
Table 69. Europe Vemurafenib Sales by Application (2023-2028) & (Tons)
Table 70. Europe Vemurafenib Revenue by Application (2017-2022) & (US$ Million)
Table 71. Europe Vemurafenib Revenue by Application (2023-2028) & (US$ Million)
Table 72. Europe Vemurafenib Sales by Country (2017-2022) & (Tons)
Table 73. Europe Vemurafenib Sales by Country (2023-2028) & (Tons)
Table 74. Europe Vemurafenib Revenue by Country (2017-2022) & (US$ Million)
Table 75. Europe Vemurafenib Revenue by Country (2023-2028) & (US$ Million)
Table 76. Asia Pacific Vemurafenib Sales by Type (2017-2022) & (Tons)
Table 77. Asia Pacific Vemurafenib Sales by Type (2023-2028) & (Tons)
Table 78. Asia Pacific Vemurafenib Revenue by Type (2017-2022) & (US$ Million)
Table 79. Asia Pacific Vemurafenib Revenue by Type (2023-2028) & (US$ Million)
Table 80. Asia Pacific Vemurafenib Sales by Application (2017-2022) & (Tons)
Table 81. Asia Pacific Vemurafenib Sales by Application (2023-2028) & (Tons)
Table 82. Asia Pacific Vemurafenib Revenue by Application (2017-2022) & (US$ Million)
Table 83. Asia Pacific Vemurafenib Revenue by Application (2023-2028) & (US$ Million)
Table 84. Asia Pacific Vemurafenib Sales by Region (2017-2022) & (Tons)
Table 85. Asia Pacific Vemurafenib Sales by Region (2023-2028) & (Tons)
Table 86. Asia Pacific Vemurafenib Revenue by Region (2017-2022) & (US$ Million)
Table 87. Asia Pacific Vemurafenib Revenue by Region (2023-2028) & (US$ Million)
Table 88. Latin America Vemurafenib Sales by Type (2017-2022) & (Tons)
Table 89. Latin America Vemurafenib Sales by Type (2023-2028) & (Tons)
Table 90. Latin America Vemurafenib Revenue by Type (2017-2022) & (US$ Million)
Table 91. Latin America Vemurafenib Revenue by Type (2023-2028) & (US$ Million)
Table 92. Latin America Vemurafenib Sales by Application (2017-2022) & (Tons)
Table 93. Latin America Vemurafenib Sales by Application (2023-2028) & (Tons)
Table 94. Latin America Vemurafenib Revenue by Application (2017-2022) & (US$ Million)
Table 95. Latin America Vemurafenib Revenue by Application (2023-2028) & (US$ Million)
Table 96. Latin America Vemurafenib Sales by Country (2017-2022) & (Tons)
Table 97. Latin America Vemurafenib Sales by Country (2023-2028) & (Tons)
Table 98. Latin America Vemurafenib Revenue by Country (2017-2022) & (US$ Million)
Table 99. Latin America Vemurafenib Revenue by Country (2023-2028) & (US$ Million)
Table 100. Middle East and Africa Vemurafenib Sales by Type (2017-2022) & (Tons)
Table 101. Middle East and Africa Vemurafenib Sales by Type (2023-2028) & (Tons)
Table 102. Middle East and Africa Vemurafenib Revenue by Type (2017-2022) & (US$ Million)
Table 103. Middle East and Africa Vemurafenib Revenue by Type (2023-2028) & (US$ Million)
Table 104. Middle East and Africa Vemurafenib Sales by Application (2017-2022) & (Tons)
Table 105. Middle East and Africa Vemurafenib Sales by Application (2023-2028) & (Tons)
Table 106. Middle East and Africa Vemurafenib Revenue by Application (2017-2022) & (US$ Million)
Table 107. Middle East and Africa Vemurafenib Revenue by Application (2023-2028) & (US$ Million)
Table 108. Middle East and Africa Vemurafenib Sales by Country (2017-2022) & (Tons)
Table 109. Middle East and Africa Vemurafenib Sales by Country (2023-2028) & (Tons)
Table 110. Middle East and Africa Vemurafenib Revenue by Country (2017-2022) & (US$ Million)
Table 111. Middle East and Africa Vemurafenib Revenue by Country (2023-2028) & (US$ Million)
Table 112. Fermion Corporation Information
Table 113. Fermion Description and Major Businesses
Table 114. Fermion Vemurafenib Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2017-2022)
Table 115. Fermion Vemurafenib Product Model Numbers, Pictures, Descriptions and Specifications
Table 116. Fermion Recent Development
Table 117. Roche Corporation Information
Table 118. Roche Description and Major Businesses
Table 119. Roche Vemurafenib Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2017-2022)
Table 120. Roche Vemurafenib Product Model Numbers, Pictures, Descriptions and Specifications
Table 121. Roche Recent Development
Table 122. Haohong Biotechnology Corporation Information
Table 123. Haohong Biotechnology Description and Major Businesses
Table 124. Haohong Biotechnology Vemurafenib Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2017-2022)
Table 125. Haohong Biotechnology Vemurafenib Product Model Numbers, Pictures, Descriptions and Specifications
Table 126. Haohong Biotechnology Recent Development
Table 127. LGM Pharma Corporation Information
Table 128. LGM Pharma Description and Major Businesses
Table 129. LGM Pharma Vemurafenib Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2017-2022)
Table 130. LGM Pharma Vemurafenib Product Model Numbers, Pictures, Descriptions and Specifications
Table 131. LGM Pharma Recent Development
Table 132. KeChow Pharma Corporation Information
Table 133. KeChow Pharma Description and Major Businesses
Table 134. KeChow Pharma Vemurafenib Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2017-2022)
Table 135. KeChow Pharma Vemurafenib Product Model Numbers, Pictures, Descriptions and Specifications
Table 136. KeChow Pharma Recent Development
Table 137. Hetero Corporation Information
Table 138. Hetero Description and Major Businesses
Table 139. Hetero Vemurafenib Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2017-2022)
Table 140. Hetero Vemurafenib Product Model Numbers, Pictures, Descriptions and Specifications
Table 141. Hetero Recent Development
Table 142. ANQING CHICO Corporation Information
Table 143. ANQING CHICO Description and Major Businesses
Table 144. ANQING CHICO Vemurafenib Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2017-2022)
Table 145. ANQING CHICO Vemurafenib Product Model Numbers, Pictures, Descriptions and Specifications
Table 146. ANQING CHICO Recent Development
Table 147. Shanghai Shenyue Biotechnology Corporation Information
Table 148. Shanghai Shenyue Biotechnology Description and Major Businesses
Table 149. Shanghai Shenyue Biotechnology Vemurafenib Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2017-2022)
Table 150. Shanghai Shenyue Biotechnology Vemurafenib Product Model Numbers, Pictures, Descriptions and Specifications
Table 151. Shanghai Shenyue Biotechnology Recent Development
Table 152. Kaiyu Pharmatech Corporation Information
Table 153. Kaiyu Pharmatech Description and Major Businesses
Table 154. Kaiyu Pharmatech Vemurafenib Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2017-2022)
Table 155. Kaiyu Pharmatech Vemurafenib Product Model Numbers, Pictures, Descriptions and Specifications
Table 156. Kaiyu Pharmatech Recent Development
Table 157. Key Raw Materials Lists
Table 158. Raw Materials Key Suppliers Lists
Table 159. Vemurafenib Distributors List
Table 160. Vemurafenib Customers List
Table 161. Vemurafenib Market Trends
Table 162. Vemurafenib Market Drivers
Table 163. Vemurafenib Market Challenges
Table 164. Vemurafenib Market Restraints
Table 165. Research Programs/Design for This Report
Table 166. Key Data Information from Secondary Sources
Table 167. Key Data Information from Primary Sources
List of Figures
Figure 1. Vemurafenib Product Picture
Figure 2. Global Vemurafenib Market Share by Type in 2021 & 2028
Figure 3. Purity ≥99% Product Picture
Figure 4. Purity ≥99.5% Product Picture
Figure 5. Global Vemurafenib Market Share by Application in 2021 & 2028
Figure 6. Pharmaceutical
Figure 7. Research Reagents
Figure 8. Other
Figure 9. Vemurafenib Report Years Considered
Figure 10. Global Vemurafenib Capacity, Production and Utilization (2017-2028) & (Tons)
Figure 11. Global Vemurafenib Production Market Share by Region in Percentage: 2021 Versus 2028
Figure 12. Global Vemurafenib Production Market Share by Region (2017-2022)
Figure 13. Global Vemurafenib Production Market Share by Region (2023-2028)
Figure 14. Vemurafenib Production Growth Rate in North America (2017-2028) & (Tons)
Figure 15. Vemurafenib Production Growth Rate in Europe (2017-2028) & (Tons)
Figure 16. Vemurafenib Production Growth Rate in China (2017-2028) & (Tons)
Figure 17. Global Vemurafenib Sales 2017-2028 (Tons)
Figure 18. Global Vemurafenib Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 19. Global Vemurafenib Revenue 2017-2028 (US$ Million)
Figure 20. Global Vemurafenib Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 21. Global Vemurafenib Sales Market Share by Region (2017-2022)
Figure 22. Global Vemurafenib Sales Market Share by Region (2023-2028)
Figure 23. North America Vemurafenib Sales YoY (2017-2028) & (Tons)
Figure 24. North America Vemurafenib Revenue YoY (2017-2028) & (US$ Million)
Figure 25. Europe Vemurafenib Sales YoY (2017-2028) & (Tons)
Figure 26. Europe Vemurafenib Revenue YoY (2017-2028) & (US$ Million)
Figure 27. Asia-Pacific Vemurafenib Sales YoY (2017-2028) & (Tons)
Figure 28. Asia-Pacific Vemurafenib Revenue YoY (2017-2028) & (US$ Million)
Figure 29. Latin America Vemurafenib Sales YoY (2017-2028) & (Tons)
Figure 30. Latin America Vemurafenib Revenue YoY (2017-2028) & (US$ Million)
Figure 31. Middle East & Africa Vemurafenib Sales YoY (2017-2028) & (Tons)
Figure 32. Middle East & Africa Vemurafenib Revenue YoY (2017-2028) & (US$ Million)
Figure 33. The Vemurafenib Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 34. The Top 5 and 10 Largest Manufacturers of Vemurafenib in the World: Market Share by Vemurafenib Revenue in 2021
Figure 35. Vemurafenib Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 36. Global Vemurafenib Sales Market Share by Type (2017-2028)
Figure 37. Global Vemurafenib Revenue Market Share by Type (2017-2028)
Figure 38. Global Vemurafenib Sales Market Share by Application (2017-2028)
Figure 39. Global Vemurafenib Revenue Market Share by Application (2017-2028)
Figure 40. North America Vemurafenib Sales Market Share by Type (2017-2028)
Figure 41. North America Vemurafenib Revenue Market Share by Type (2017-2028)
Figure 42. North America Vemurafenib Sales Market Share by Application (2017-2028)
Figure 43. North America Vemurafenib Revenue Market Share by Application (2017-2028)
Figure 44. North America Vemurafenib Sales Share by Country (2017-2028)
Figure 45. North America Vemurafenib Revenue Share by Country (2017-2028)
Figure 46. United States Vemurafenib Revenue (2017-2028) & (US$ Million)
Figure 47. Canada Vemurafenib Revenue (2017-2028) & (US$ Million)
Figure 48. Europe Vemurafenib Sales Market Share by Type (2017-2028)
Figure 49. Europe Vemurafenib Revenue Market Share by Type (2017-2028)
Figure 50. Europe Vemurafenib Sales Market Share by Application (2017-2028)
Figure 51. Europe Vemurafenib Revenue Market Share by Application (2017-2028)
Figure 52. Europe Vemurafenib Sales Share by Country (2017-2028)
Figure 53. Europe Vemurafenib Revenue Share by Country (2017-2028)
Figure 54. Germany Vemurafenib Revenue (2017-2028) & (US$ Million)
Figure 55. France Vemurafenib Revenue (2017-2028) & (US$ Million)
Figure 56. U.K. Vemurafenib Revenue (2017-2028) & (US$ Million)
Figure 57. Italy Vemurafenib Revenue (2017-2028) & (US$ Million)
Figure 58. Russia Vemurafenib Revenue (2017-2028) & (US$ Million)
Figure 59. Asia Pacific Vemurafenib Sales Market Share by Type (2017-2028)
Figure 60. Asia Pacific Vemurafenib Revenue Market Share by Type (2017-2028)
Figure 61. Asia Pacific Vemurafenib Sales Market Share by Application (2017-2028)
Figure 62. Asia Pacific Vemurafenib Revenue Market Share by Application (2017-2028)
Figure 63. Asia Pacific Vemurafenib Sales Share by Region (2017-2028)
Figure 64. Asia Pacific Vemurafenib Revenue Share by Region (2017-2028)
Figure 65. China Vemurafenib Revenue (2017-2028) & (US$ Million)
Figure 66. Japan Vemurafenib Revenue (2017-2028) & (US$ Million)
Figure 67. South Korea Vemurafenib Revenue (2017-2028) & (US$ Million)
Figure 68. India Vemurafenib Revenue (2017-2028) & (US$ Million)
Figure 69. Australia Vemurafenib Revenue (2017-2028) & (US$ Million)
Figure 70. China Taiwan Vemurafenib Revenue (2017-2028) & (US$ Million)
Figure 71. Indonesia Vemurafenib Revenue (2017-2028) & (US$ Million)
Figure 72. Thailand Vemurafenib Revenue (2017-2028) & (US$ Million)
Figure 73. Malaysia Vemurafenib Revenue (2017-2028) & (US$ Million)
Figure 74. Latin America Vemurafenib Sales Market Share by Type (2017-2028)
Figure 75. Latin America Vemurafenib Revenue Market Share by Type (2017-2028)
Figure 76. Latin America Vemurafenib Sales Market Share by Application (2017-2028)
Figure 77. Latin America Vemurafenib Revenue Market Share by Application (2017-2028)
Figure 78. Latin America Vemurafenib Sales Share by Country (2017-2028)
Figure 79. Latin America Vemurafenib Revenue Share by Country (2017-2028)
Figure 80. Mexico Vemurafenib Revenue (2017-2028) & (US$ Million)
Figure 81. Brazil Vemurafenib Revenue (2017-2028) & (US$ Million)
Figure 82. Argentina Vemurafenib Revenue (2017-2028) & (US$ Million)
Figure 83. Middle East and Africa Vemurafenib Sales Market Share by Type (2017-2028)
Figure 84. Middle East and Africa Vemurafenib Revenue Market Share by Type (2017-2028)
Figure 85. Middle East and Africa Vemurafenib Sales Market Share by Application (2017-2028)
Figure 86. Middle East and Africa Vemurafenib Revenue Market Share by Application (2017-2028)
Figure 87. Middle East and Africa Vemurafenib Sales Share by Country (2017-2028)
Figure 88. Middle East and Africa Vemurafenib Revenue Share by Country (2017-2028)
Figure 89. Turkey Vemurafenib Revenue (2017-2028) & (US$ Million)
Figure 90. Saudi Arabia Vemurafenib Revenue (2017-2028) & (US$ Million)
Figure 91. UAE Vemurafenib Revenue (2017-2028) & (US$ Million)
Figure 92. Vemurafenib Value Chain
Figure 93. Vemurafenib Production Process
Figure 94. Channels of Distribution
Figure 95. Distributors Profiles
Figure 96. Bottom-up and Top-down Approaches for This Report
Figure 97. Data Triangulation
Figure 98. Key Executives Interviewed

---